Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Executive Summary | 1 | 2 |
| 2 Table of Contents | 3 | 7 |
| 2.1 List of Tables | 5 | 2 |
| 2.2 List of Figures | 7 | 3 |
| 3 Global Urological Disorders Market: Introduction | 10 | 2 |
| 3.1 GBI Research Report Guidance | 11 | 1 |
| 4 Global Urological Disorders Market: Market Overview | 12 | 12 |
| 4.1 Introduction | 12 | 1 |
| 4.2 Revenue Forecasts for the Global Urological Disorders Market | 13 | 1 |
| 4.2.1 Sales Value | 13 | 1 |
| 4.2.2 Annual Cost of Therapy | 14 | 1 |
| Treatment Usage Patterns | 15 | 2 |
| 4.2.3.1 Diseased Population | 17 | 1 |
| 4.2.3.2 Treatment Seeking Population | 18 | 1 |
| 4.2.3.3 Diagnosed Population | 19 | 1 |
| 4.2.3.4 Prescription Population | 20 | 1 |
| 4.2.4 Generics Share in the Global Urological Disorders Market | 20 | 2 |
| 4.3 Urological Disorders Market Drivers | 22 | 1 |
| 4.3.1 Steady Increase in the UI and BPH Prevalence Population | 22 | 1 |
| 4.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH | 22 | 1 |
| 4.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable | 22 | 1 |
| 4.4 Urological Disorders Market Restraints | 23 | 1 |
| 4.4.1 Unwillingness to Seek Medical Help for UI | 23 | 1 |
| 4.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues | 23 | 1 |
| 4.4.3 Non Pharmacological Therapy Recommended for UI and BPH | 23 | 1 |
| 5 Global Urological Disorders Market: Therapeutic Landscape | 24 | 40 |
| 5.1 Benign Prostatic Hyperplasia Market | 24 | 1 |
| 5.1.1 Introduction | 24 | 1 |
| 5.1.2 Sales Value | 24 | 2 |
| 5.1.3 Annual Cost of Therapy | 26 | 1 |
| 5.1.4 Treatment Usage Patterns | 27 | 1 |
| 5.1.4.1 Diseased Population | 28 | 1 |
| 5.1.4.2 Treatment Seeking Population | 29 | 1 |
| 5.1.4.3 Diagnosed Population | 30 | 1 |
| 5.1.4.4 Prescription Population | 31 | 1 |
| 5.1.5 Market Share by Geography | 32 | 3 |
| 5.1.6 Generics Share of the Global BPH Market | 35 | 1 |
| 5.2 Urinary Incontinence (UI) Market | 36 | 1 |
| 5.2.1 Introduction | 36 | 1 |
| 5.2.2 Sales Value | 37 | 2 |
| 5.2.3 Annual Cost of Therapy | 39 | 1 |
| 5.2.4 Treatment Usage Patterns | 40 | 1 |
| 5.2.4.1 Diseased Population | 41 | 1 |
| 5.2.4.2 Treatment Seeking Population | 42 | 1 |
| 5.2.4.3 Diagnosed Population | 43 | 1 |
| 5.2.4.4 Prescription Population | 44 | 1 |
| 5.2.5 Market Share by Geography | 45 | 4 |
| 5.2.6 Generics Share in the Global UI Market | 49 | 2 |
| 5.3 Urinary Tract Infections Market | 51 | 1 |
| 5.3.1 Introduction | 51 | 1 |
| 5.3.2 Sales Value | 51 | 2 |
| 5.3.3 Annual Cost of Therapy | 53 | 1 |
| 5.3.4 Treatment Usage Patterns | 54 | 1 |
| 5.3.4.1 Diseased Population | 55 | 1 |
| 5.3.4.2 Treatment Seeking Population | 56 | 1 |
| 5.3.4.3 Diagnosed Population | 57 | 1 |
| 5.3.4.4 Prescription Population | 58 | 1 |
| 5.3.5 Market Share by Geography | 59 | 3 |
| 5.3.6 Generics Share of the Global UTI Market | 62 | 2 |
| 6 Global Urological Disorders Market: Geographical Landscape | 64 | 26 |
| 6.1 Geographical Break-up | 64 | 3 |
| 6.2 The US | 67 | 1 |
| 6.2.1 Sales Value | 67 | 1 |
| 6.2.2 Annual Cost of Therapy | 68 | 1 |
| 6.2.3 Treatment Usage Patterns | 69 | 1 |
| 6.2.3.1 Diseased Population | 70 | 1 |
| 6.2.3.2 Treatment Seeking Population | 71 | 2 |
| 6.2.3.3 Diagnosed Population | 73 | 1 |
| 6.2.3.4 Prescription Population | 74 | 1 |
| 6.3 Top Five Countries in Europe | 75 | 1 |
| 6.3.1 Sales Value | 75 | 1 |
| 6.3.2 Annual Cost of Therapy | 76 | 1 |
| 6.3.3 Treatment Usage Patterns | 77 | 2 |
| 6.3.3.1 Diseased Population | 79 | 1 |
| 6.3.3.2 Treatment Seeking Population | 80 | 1 |
| 6.3.3.3 Diagnosed Population | 81 | 1 |
| 6.3.3.4 Prescription Population | 82 | 1 |
| 6.4 Japan | 83 | 1 |
| 6.4.1 Sales Value | 83 | 1 |
| 6.4.2 Annual Cost of Therapy | 84 | 1 |
| 6.4.3 Treatment Usage Patterns | 85 | 1 |
| 6.4.3.1 Diseased Population | 86 | 1 |
| 6.4.3.2 Treatment Seeking Population | 87 | 1 |
| 6.4.3.3 Diagnosed Population | 88 | 1 |
| 6.4.3.4 Prescription Population | 89 | 1 |
| 7 Global Urological Disorders Market: Pipeline Analysis | 90 | 11 |
| 7.1 Introduction | 90 | 1 |
| 7.1.1 Research and Development Pipeline UI | 91 | 2 |
| 7.1.2 Research and Development Pipeline BPH | 93 | 2 |
| 7.1.3 Research and Development Pipeline UTI | 95 | 2 |
| 7.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market | 97 | 1 |
| 7.2.1 Botulinum Toxin A | 97 | 1 |
| 7.2.1.1 Introduction | 97 | 1 |
| 7.2.1.2 Efficacy | 97 | 1 |
| 7.2.1.3 Safety | 97 | 1 |
| 7.2.1.4 Clinical Study Details | 97 | 1 |
| 7.2.2 YM178 | 98 | 1 |
| 7.2.2.1 Introduction | 98 | 1 |
| 7.2.2.2 Efficacy | 98 | 1 |
| 7.2.2.3 Safety | 98 | 1 |
| 7.2.2.4 Clinical Study Details | 98 | 1 |
| 7.2.3 NX-1207 | 98 | 1 |
| 7.2.3.1 Introduction | 98 | 1 |
| 7.2.3.2 Efficacy | 98 | 1 |
| 7.2.3.3 Safety Profile | 99 | 1 |
| 7.2.3.4 Clinical Study Details | 99 | 1 |
| 7.2.4 PRX302 | 99 | 1 |
| 7.2.4.1 Introduction | 99 | 1 |
| 7.2.4.2 Efficacy | 99 | 1 |
| 7.2.4.3 Safety | 99 | 1 |
| 7.2.4.4 Clinical Study Details | 99 | 1 |
| 7.2.5 NXL104/ceftazidime | 100 | 1 |
| 7.2.5.1 Introduction | 100 | 1 |
| 7.2.5.2 Efficacy | 100 | 1 |
| 7.2.5.3 Safety | 100 | 1 |
| 7.2.5.4 Clinical Study Details | 100 | 1 |
| 8 Global Urological Disorders Market: Competitive Landscape | 101 | 9 |
| 8.1 Market Share Analysis: Urological Disorders | 101 | 2 |
| 8.2 Competitive Profiling | 103 | 1 |
| 8.2.1 Astellas Pharma | 103 | 1 |
| 8.2.1.1 Product Portfolio | 103 | 1 |
| 8.2.2 Johnson and Johnson (J&J) | 104 | 1 |
| 8.2.2.1 Product Portfolio | 105 | 1 |
| 8.2.3 Pfizer | 106 | 1 |
| 8.2.3.1 Product Portfolio | 106 | 1 |
| 8.2.4 GlaxoSmithKilne (GSK) | 107 | 1 |
| 8.2.4.1 Product Portfolio | 107 | 1 |
| 8.2.5 Sanofi-Aventis | 108 | 1 |
| 8.2.5.1 Product Portfolio | 109 | 1 |
| 9 Global Urological Disorders Market: Strategic Consolidations | 110 | 10 |
| 9.1 Overview | 110 | 2 |
| 9.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter &Gamble in October 2009 | 112 | 1 |
| 9.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007 | 112 | 1 |
| 9.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006 | 112 | 1 |
| 9.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006 | 112 | 1 |
| 9.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005 | 112 | 1 |
| 9.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004 | 112 | 1 |
| 9.2 R&D Licensing Agreements | 113 | 1 |
| Deals by Indication | 113 | 1 |
| 9.2.2 Deals by Phase | 114 | 1 |
| 9.2.3 Deals by Geography | 114 | 1 |
| 9.2.4 Deals by Licensing Type | 115 | 1 |
| 9.2.5 Deals by Value ($) | 115 | 1 |
| 9.2.6 Phase I | 116 | 1 |
| 9.2.6.1 MN-246 | 116 | 1 |
| 9.2.7 Phase II | 117 | 1 |
| 9.2.7.1 PRX302 | 117 | 1 |
| 9.2.7.2 GRT 203 | 117 | 1 |
| 9.2.7.3 PSD 506 | 117 | 1 |
| 9.2.8 Approved | 118 | 1 |
| 9.2.8.1 Silodyx | 118 | 1 |
| 9.2.8.2 Silodosin | 118 | 1 |
| 9.2.8.3 Urief | 118 | 1 |
| 9.2.8.4 SANCTURA XR | 118 | 1 |
| 9.2.8.5 Kentera | 119 | 1 |
| 10 Global Urological Disorders Market: Appendix | 120 | 6 |
| 10.1 Market Definitions | 120 | 1 |
| 10.2 Abbreviations | 120 | 1 |
| 10.3 Research Methodology | 121 | 4 |
| 10.3.1 Coverage | 121 | 1 |
| 10.3.2 Secondary Research | 121 | 1 |
| 10.3.3 Primary Research | 122 | 1 |
| 10.3.4 Forecasts | 122 | 1 |
| 10.3.4.1 Epidemiology-based Forecasting | 122 | 2 |
| 10.3.5 Expert Panel Validation | 124 | 1 |
| 10.4 Contact Us | 125 | 1 |
| 10.5 Disclaimer | 125 | 1 |
| 10.6 Sources | 125 | 1 |